RecruitingPhase 4NCT05517655
BEGIN Novel ImagiNG Biomarkers
Sponsor
Children's Hospital Medical Center, Cincinnati
Enrollment
44 participants
Start Date
May 1, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
To determine the treatment effect of triple-combination therapy in 6-8 year olds after presumed FDA approval, using rapid structural and functional pulmonary and abdominal MRI (UTE and 129Xe).
Eligibility
Min Age: 6 YearsMax Age: 8 Years
Inclusion Criteria10
- Written informed consent (and assent where appropriate) obtained from the subject or subject's legal representative.
- Willingness to adhere to the study-visit schedule and other protocol requirements.
- Ages 6-8 years old at baseline MRI visit (may be enrolled up to 60 days before 6th birthday).
- Documentation of CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the following criteria:
- Sweat chloride equal to or greater than 60 mEq/liter by quantitative pilocarpine iontophoresis test
- Two well-characterized mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
- Physician intent to prescribe triple-combination therapy
- Clinically-stable with no respiratory tract infection at the time of enrollment.
- No change in chronic maintenance therapies in the 28 days prior to enrollment.
- Ability to cooperate with MRI procedures
Exclusion Criteria9
- Individuals currently on ivacaftor therapy (including Kalydeco, Orkambi, and Symdeko) and with at least one gating mutation. Gating mutations include G551D, G178R, S549N, S549R, G551S, G970R, G1244E, S1251N, S1255P, or G1349D.
- Acute respiratory symptoms (e.g. wheezing) at the time of the MRI.
- Acute respiratory infection, defined as increased cough, wheezing or respiratory rate in the 28 days prior to enrollment.
- Chronic lung disease not related to CF
- Chronic liver disease not related to CF
- Acute pancreatitis, defined by clinical criteria (45).
- Chronic pancreatic disease not related to CF.
- Physical findings that would compromise the safety of the subject or the quality of the study data as determined at the discretion of the site investigator.
- Any other condition that, in the opinion of the Site Investigator/designee, would preclude informed consent or assent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUG129Xe
Rapid spatial mapping of lung, liver, and pancreatic structure and function is now possible with a combination of hyperpolarized 129Xe and traditional proton MRI, all absent sedation and ionizing radiation.
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05517655
Related Trials
Natural History of Noncirrhotic Portal Hypertension
NCT024177401 location
Role of Genetic Factors in the Development of Lung Disease
NCT000015322 locations
Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
NCT061474141 location
Impact of Sinus Surgery on Individuals With Cystic Fibrosis
NCT044694399 locations
Maralixibat in Patients With Cystic Fibrosis and Constipation
NCT064133681 location